Literature DB >> 9067650

Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population: proposal for response criteria.

M J Rodrigo1, M Miravitlles, M J Cruz, J de Gracia, M Vendrell, C Pascual, F Morell.   

Abstract

The aim of the study was to standardize an enzyme-linked immunosorbent assay (ELISA) method for the quantification of immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine and to establish the criteria for a normal response to the vaccine. Forty healthy individuals (20 women and 20 men; mean age, 29 years) were studied. All were vaccinated with the 23-valent pneumococcal vaccine; blood samples were drawn just prior to and 3 weeks after immunization. Quantification of specific IgG and its subclasses was performed by an ELISA with the vaccine as the antigen. The linearity of the ELISA method was demonstrated by the similar slopes of the linear regression lines generated from the titration of sera with different antibody concentrations. The specificity of the antibodies against the vaccine was demonstrated by (i) an absorption test with pneumococcal vaccine, (ii) a cross-reactivity experiment with Haemophilus influenzae type b polysaccharide, and (iii) affinity chromatography with protein A-Sepharose. Response to the vaccine was defined by using the lower level of the 90% probability interval (one-tailed) for postimmunization-specific IgG, IgG1, and IgG2. By using this cutoff, responders were considered to be those with an absolute increase in antibody titers higher than 395 arbitrary units/ml for IgG, 0.350 A450 units for IgG1, and 0.314 A450 units for IgG2. Overall, 20 (50%) subjects had IgG, IgG1, and IgG2 responses, 9 (22.5%) had IgG and IgG2 responses, 4 (10%) had IgG1 responses, 3 (7.5%) had IgG and IgG1 responses, and 4 (10%) were nonresponders. Ninety percent of our population responded to the 23-valent pneumococcal vaccine. Up to 10% of healthy individuals may respond to an IgG subclass without significant increases in total IgG titers. The ELISA method that is described may be useful for evaluating the specific antibody response against polysaccharides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067650      PMCID: PMC170496          DOI: 10.1128/cdli.4.2.168-172.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  26 in total

Review 1.  Pneumococcal disease: prospects for a new generation of vaccines.

Authors:  G R Siber
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

2.  Amplification of the enzyme-linked immunosorbent assay for measuring allergen-specific IgE and IgG antibody.

Authors:  W J Metzger; J E Butler; P Swanson; E Reinders; H B Richerson
Journal:  Clin Allergy       Date:  1981-11

3.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.

Authors:  G R Siber; P H Schur; A C Aisenberg; S A Weitzman; G Schiffman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

4.  Antibody activity of IgG subclasses against pneumococcal polysaccharides after vaccination.

Authors:  B Rynnel-Dagöö; A Freijd; K Prellner
Journal:  Am J Otolaryngol       Date:  1985 Jul-Aug       Impact factor: 1.808

5.  Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine.

Authors:  F Mascart-Lemone; M Gérard; M Libin; A Crusiaux; P Franchioly; A Lambrechts; M Goldman; N Clumeck
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

6.  Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine.

Authors:  P J Weiss; M R Wallace; E C Oldfield; J O'Brien; E N Janoff
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

7.  Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency.

Authors:  D T Umetsu; D M Ambrosino; I Quinti; G R Siber; R S Geha
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

8.  IgG subclass deficiencies associated with bronchiectasis.

Authors:  J De Gracia; M J Rodrigo; F Morell; M Vendrell; M Miravitlles; M J Cruz; R Codina; J M Bofill
Journal:  Am J Respir Crit Care Med       Date:  1996-02       Impact factor: 21.405

Review 9.  Assessment of the antibody response to pneumococcal vaccine in high-risk populations.

Authors:  S H Landesman; G Schiffman
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

10.  Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice.

Authors:  E Alonso De Velasco; B A Dekker; A F Verheul; R G Feldman; J Verhoef; H Snippe
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

View more
  3 in total

Review 1.  Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Authors:  Paul Balmer; Andrew J Cant; Ray Borrow
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

2.  Detection of specific antibodies to pigeon serum and bloom antigens by enzyme linked immunosorbent assay in pigeon breeder's disease.

Authors:  M J Rodrigo; M I Benavent; M J Cruz; M Rosell; C Murio; C Pascual; F Morell
Journal:  Occup Environ Med       Date:  2000-03       Impact factor: 4.402

3.  Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma) RIIa polymorphism characteristics.

Authors:  A Payeras; P Martinez; J Milà; M Riera; A Pareja; J Casal; N Matamoros
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.